ANSWER: C

Rationale:

The correct answer is C. The SAMSON trial (Self-Assessment Method for Statin Side-effects Or Nocebo, 2020) was a double-blind n-of-1 crossover study that enrolled patients with prior self-reported statin intolerance and alternated months of statin therapy, placebo, and no treatment in a blinded fashion. The principal finding was that approximately 90% of muscle symptom intensity reported during statin months was replicated during placebo months — directly quantifying the nocebo contribution as the dominant source of reported muscle symptoms in this population. This figure has major clinical implications: the overwhelming majority of patients who have discontinued statins for perceived muscle intolerance carry a symptom burden driven primarily by negative expectation rather than statin pharmacology, and most can be successfully re-challenged with appropriate patient education or blinded exposure strategies.

• Option A: Option A is incorrect because it inverts the attribution: A states that statin pharmacology accounts for approximately 90% of symptoms, which is the opposite of the trial finding — it is the nocebo effect, not pharmacology, that accounts for approximately 90%.
• Option B: Option B is incorrect because the SAMSON trial did not find significantly higher muscle symptom scores during statin months — symptom scores during statin and placebo months were similar, which is precisely what revealed the nocebo contribution.
• Option D: Option D is incorrect because the trial did not find a roughly equal 50/50 split between pharmacological and nocebo contributions. The nocebo contribution was substantially larger, accounting for approximately 90% of symptom intensity.
• Option E: Option E is incorrect because the SAMSON trial did not conclude that blinded rechallenge is unreliable. On the contrary, the trial's design and findings support blinded rechallenge as a clinically valuable strategy for distinguishing nocebo-driven intolerance from genuine pharmacological myopathy.

ANSWER: A

Rationale:

The correct answer is A. The SLCO1B1 521T>C variant (rs4149056) reduces the functional activity of the OATP1B1 hepatic uptake transporter. Under normal circumstances, OATP1B1 mediates the uptake of statins from portal blood into hepatocytes — the site of therapeutic action (HMG-CoA reductase inhibition in the liver). When OATP1B1 activity is reduced by the 521C variant, less statin is extracted into the liver on the first pass, and more remains in systemic circulation. This increased systemic plasma exposure translates directly into higher skeletal muscle statin concentrations, shifting the therapeutic index unfavorably: less drug reaches the target organ (liver) and more accumulates in the tissue responsible for toxicity (skeletal muscle). This mechanism is most clinically relevant for simvastatin, which has the highest dependence on OATP1B1-mediated hepatic uptake among the commonly used statins.

• Option B: Option B is incorrect because the 521C variant reduces OATP1B1 activity — it does not increase it. Increased hepatic uptake would be the opposite of what this variant produces and would, if anything, reduce systemic exposure.
• Option C: Option C is incorrect because the SLCO1B1 521C variant does not upregulate CYP3A4. The mechanism of myopathy risk from this variant is mediated entirely through the OATP1B1 transporter and increased systemic exposure — not through altered cytochrome P450 3A4 (CYP3A4) enzyme activity or myotoxic lactone metabolite generation.
• Option D: Option D is incorrect because OATP1B1 is a hepatic uptake transporter, not a skeletal muscle membrane transporter. The myopathy risk arises from increased systemic plasma concentrations — not from direct uptake into myocytes via OATP1B1.
• Option E: Option E is incorrect because OATP1B1 is not a renal tubular transporter. Its primary function is hepatic uptake from portal blood. Renal elimination mechanisms are distinct from the OATP1B1-mediated hepatic first-pass extraction that this variant disrupts.

ANSWER: E

Rationale:

The correct answer is E. This clinical presentation is diagnostic of statin-associated autoimmune myopathy (SAAM), also termed immune-mediated necrotizing myopathy (IMNM): progressive proximal weakness that worsens after statin discontinuation, markedly elevated CK at 12,400 U/L, positive anti-HMGCR antibodies, and muscle biopsy showing necrotizing myopathy with minimal inflammatory infiltrate. This condition is categorically different from ordinary statin-associated muscle symptoms (SAMS) — it is an immune-mediated process triggered by statin exposure in genetically susceptible individuals that persists and often progresses after drug withdrawal. The correct management is immunosuppressive therapy: high-dose corticosteroids (prednisone 1 mg/kg/day) combined with a steroid-sparing agent (methotrexate 15–25 mg/week or azathioprine 2–3 mg/kg/day) initiated simultaneously, with referral to a rheumatologist or neuromuscular specialist. Statin rechallenge is absolutely contraindicated.

• Option A: Option A is incorrect and dangerous. Anti-HMGCR antibodies in this clinical context — with worsening weakness after statin discontinuation, markedly elevated CK, and confirming biopsy — are not a false positive. Restarting atorvastatin would be contraindicated and would likely worsen the immune-mediated process.
• Option B: Option B is incorrect for the same reason: alternate-day rosuvastatin is a strategy for managing ordinary SAMS in patients without autoimmune myopathy. Any statin rechallenge is contraindicated once IMNM is confirmed, regardless of dose or dosing frequency.
• Option D: Option D is incorrect because IVIG is not first-line monotherapy for IMNM. Corticosteroids combined with a steroid-sparing immunosuppressant are the standard initial regimen. IVIG is reserved for refractory cases or as adjunctive therapy for severe weakness — not as the initial sole agent while withholding steroids.
• Option E: Option E is incorrect because lipid-lowering therapy is not permanently contraindicated across all agents in IMNM. Non-statin agents — ezetimibe, PCSK9 inhibitors, bile acid sequestrants — do not trigger the anti-HMGCR autoimmune pathway and can be used for ongoing lipid management once the patient's condition is controlled with immunosuppression.

ANSWER: B

Rationale:

The correct answer is B. In 2012, the FDA revised the prescribing information for all statin drugs to eliminate the requirement for routine periodic liver function test (LFT) monitoring during statin therapy. The regulatory basis for this revision was the accumulated evidence that: (1) true statin-induced clinically significant hepatotoxicity is rare — estimated at approximately 1–3 per 100,000 patient-years, comparable to background rates of drug-induced liver injury from other commonly prescribed medications; (2) routine periodic LFT monitoring does not detect or prevent serious liver injury, because serious statin hepatotoxicity does not occur with sufficient frequency or predictability to be intercepted by scheduled testing; and (3) routine monitoring generates patient anxiety, triggers unnecessary statin discontinuation based on asymptomatic and self-limited transaminase elevations, and imposes clinical burden without meaningful safety benefit. Current practice: obtain baseline ALT before initiating statin therapy; thereafter, liver function testing is indicated only if the patient develops symptoms suggestive of hepatotoxicity.

• Option A: Option A is incorrect because the 2012 FDA revision moved in the opposite direction — it reduced, not increased, liver monitoring requirements. Post-marketing surveillance had not identified a higher-than-expected serious hepatotoxicity rate; the data confirmed that true statin hepatotoxicity is rare.
• Option C: Option C is incorrect because the 2012 revision did not add a black-box warning for liver failure, nor did it mandate annual testing or automatic dose reduction at ALT thresholds. Black-box warnings and new dosing restrictions were not the content of the 2012 liver monitoring revision.
• Option D: Option D is incorrect because the FDA did not restrict high-intensity statin prescribing to cardiologists based on hepatotoxicity signals. No such restriction was implemented; high-intensity statins remain available to any licensed prescriber.
• Option E: Option E is incorrect because the 2012 revision applied uniformly across all statin intensities — it did not create a two-tiered system retaining quarterly monitoring for high-intensity statins while relaxing requirements for moderate-intensity agents.

ANSWER: D

Rationale:

The correct answer is D. The SHARP trial demonstrated a 17% reduction in major atherosclerotic events in the pre-dialysis CKD subgroup receiving simvastatin plus ezetimibe. This established that statin therapy (with or without ezetimibe) reduces atherosclerotic cardiovascular disease (ASCVD) events in patients with CKD who are not yet on dialysis. However, the 4D trial — which tested atorvastatin 20 mg in hemodialysis patients with type 2 diabetes — did not reduce the primary composite cardiovascular endpoint in that population. Similarly, the AURORA trial — which tested rosuvastatin 10 mg in a broad hemodialysis population — was neutral on the primary endpoint. The mechanistic explanation for this divergence is not fully established but likely reflects the different pathophysiology of cardiovascular disease in hemodialysis patients, where non-atherosclerotic causes of cardiac death (sudden death, uremic cardiomyopathy, arrhythmia) predominate over atherosclerotic causes. This pattern drives current guideline recommendations: statins are recommended for CKD patients not on dialysis and for patients at the time of dialysis initiation if already on a statin, but initiation of new statin therapy is not recommended for patients already established on maintenance hemodialysis.

• Option A: Option A is incorrect because the three trials did not all demonstrate significant benefit. The 4D and AURORA trials were neutral on their primary endpoints in hemodialysis patients — this is a fundamental finding that distinguishes dialysis from pre-dialysis CKD in the statin evidence base.
• Option B: Option B is incorrect because it reverses the actual findings: SHARP showed benefit in pre-dialysis CKD (not dialysis patients), and 4D/AURORA showed no benefit in dialysis patients (not pre-dialysis patients).
• Option C: Option C is incorrect because SHARP did demonstrate cardiovascular benefit in the CKD population. The trial was not neutral across all subgroups; the pre-dialysis subgroup showed a significant reduction in major atherosclerotic events.
• Option E: Option E is incorrect because the trials did not demonstrate equivalent benefit across dialysis and pre-dialysis populations, nor was benefit contingent on a specific LDL-C threshold. The divergence between pre-dialysis and dialysis outcomes is the defining feature of this evidence base.

ANSWER: A

Rationale:

The correct answer is A. The mechanisms of statin-associated new-onset diabetes mellitus (NODM) are multi-factorial and incompletely elucidated, but two major pathways are supported by evidence. First, statin-induced depletion of isoprenoid intermediates (geranylgeranyl pyrophosphate, farnesyl pyrophosphate) downstream of HMG-CoA reductase inhibition impairs the prenylation of small GTPases (Rac1, Rho, Ras family proteins) in skeletal muscle and adipose tissue; this reduces glucose transporter type 4 (GLUT4) expression and membrane translocation, directly impairing insulin-stimulated peripheral glucose uptake. Second, statins reduce membrane cholesterol content in pancreatic beta cells, impairing the cholesterol-dependent organization of calcium channels and SNARE protein complexes required for calcium-dependent insulin exocytosis, thereby reducing first-phase insulin secretion. The Mendelian randomization data confirming that HMG-CoA reductase loss-of-function variants independently increase diabetes risk establish that these mechanisms are intrinsic to HMG-CoA reductase inhibition itself — not idiosyncratic drug effects.

• Option B: Option B is incorrect because statins do not inhibit pancreatic glucokinase. Glucokinase is a glucose-sensing enzyme in beta cells and hepatocytes; its regulatory protein operates through a distinct binding site unrelated to the HMG-CoA reductase pathway. No evidence supports structural mimicry between statins and the glucokinase regulatory protein.
• Option C: Option C is incorrect because hepatic glycogen synthase inhibition via GSK-3 phosphorylation disruption is not an established mechanism of statin-associated diabetogenesis. While statins affect isoprenoid-dependent signaling in multiple tissues, the principal diabetogenic mechanisms operate at the level of GLUT4-mediated glucose uptake and beta-cell insulin secretion — not glycogen synthase regulation.
• Option D: Option D is incorrect because statins do not directly inhibit the insulin receptor tyrosine kinase domain. Statins have no established direct binding interaction with the insulin receptor. The diabetogenic effects of statins are mediated through upstream effects on isoprenoid and cholesterol pathways — not through receptor-level inhibition of insulin signaling.
• Option E: Option E is incorrect because statins do not inhibit lipoprotein lipase (LPL) in adipose tissue. Statins lower triglycerides modestly through LDL receptor upregulation and reduced VLDL production — not through LPL inhibition. Lipotoxicity from free fatty acid accumulation via LPL inhibition is not a recognized mechanism of statin-associated NODM.

ANSWER: C

Rationale:

The correct answer is C. Cyclosporine is a potent inhibitor of both cytochrome P450 3A4 (CYP3A4) and the organic anion-transporting polypeptide 1B1 (OATP1B1) hepatic uptake transporter. This dual inhibition markedly increases systemic plasma concentrations of virtually every statin, because most statins depend on OATP1B1 for hepatic uptake and many depend on CYP3A4 for metabolism. In heart transplant recipients, pravastatin and fluvastatin are the preferred statins based on the most extensive safety experience in this population and their demonstrably lower susceptibility to cyclosporine-mediated interaction. Importantly, there is additional clinical evidence from the Cardiac Transplant Research Database (COCPIT) trial and registry analyses that pravastatin initiated early post-transplant reduces acute rejection episodes and improves 1-year survival — an effect attributed in part to statin immunomodulatory properties (reduced natural killer cell cytotoxicity, reduced MHC class II expression) — providing a compound rationale for pravastatin in this setting. Simvastatin and lovastatin are generally avoided due to high rhabdomyolysis risk from cyclosporine-mediated CYP3A4 inhibition. option implies.

• Option A: Option A is incorrect and dangerous. Simvastatin and lovastatin are among the highest-risk statins in the setting of cyclosporine co-administration — their extensive CYP3A4 metabolism makes them particularly susceptible to cyclosporine-mediated inhibition, resulting in markedly elevated plasma concentrations and rhabdomyolysis risk. They are not preferred in this context.
• Option B: Option B is incorrect because cyclosporine has highly clinically significant effects on statin pharmacokinetics through both CYP3A4 and OATP1B1 inhibition. Ignoring these interactions and selecting atorvastatin 80 mg or rosuvastatin 40 mg at standard doses in a cyclosporine-treated patient would substantially increase myopathy risk.
• Option D: Option D is incorrect because cyclosporine inhibits both CYP3A4 and OATP1B1 — not OATP1B1 alone. Furthermore, rosuvastatin is not unaffected by cyclosporine; rosuvastatin is an OATP1B1 substrate, and its plasma concentrations are significantly increased by cyclosporine co-administration. Rosuvastatin can be used at reduced doses with monitoring but is not the straightforward safe choice this
• Option E: Option E is incorrect because cyclosporine's primary pharmacokinetic interactions with statins operate through CYP3A4 and OATP1B1 — not through selective CYP2C9 inhibition. While cyclosporine does have some CYP2C9 inhibitory activity, characterizing it as a selective CYP2C9 inhibitor misrepresents its interaction profile and would lead to incorrect statin selection.

ANSWER: B

Rationale:

The correct answer is B. The stepwise management of suspected SAMS is well-defined. At a CK of 8× ULN with muscle symptoms: the statin should be held temporarily (Step 2 of the management algorithm). The threshold for more urgent action is CK ≥10× ULN with symptoms — at that threshold, the statin is discontinued and rechallenge should not occur until CK returns to normal. At 8× ULN, the patient is below that threshold, and the appropriate course is a drug holiday (typically 4–6 weeks) with symptom reassessment. If symptoms resolve and CK normalizes with the drug holiday, rechallenge — with the same statin at a lower dose or an alternative statin with a more favorable muscle symptom profile (rosuvastatin 5–10 mg, pravastatin 40 mg, fluvastatin 80 mg XL) — is the evidence-based next step. Persistent symptoms after drug holiday suggest an alternative etiology, not ongoing statin effect.

• Option A: Option A is incorrect because continuing the statin at the same dose when a patient has symptoms and CK elevation at 8× ULN is not appropriate management. A CK at 8× ULN with active symptoms warrants at minimum a temporary drug holiday, not continued exposure.
• Option C: Option C is incorrect because a CK of 8× ULN with symptoms does not mandate permanent statin discontinuation or lifelong avoidance. SAMS management is stepwise and rechallenge is expected in most patients. Complete lifelong avoidance of all statins is rarely necessary and represents a failure of the rechallenge process. Permanent discontinuation based on a single episode with CK below 10× ULN would deprive patients of clinically important cardiovascular risk reduction.
• Option D: Option D is incorrect because there are no features of rhabdomyolysis in this presentation. Rhabdomyolysis is characterized by CK typically >40× ULN, myoglobinuria (tea-colored urine), and acute kidney injury risk. CK at 8× ULN with muscle aching does not meet the threshold for presumed rhabdomyolysis, and initiating IV fluids and bicarbonate is not indicated in this clinical scenario.
• Option E: Option E is incorrect because switching to high-dose rosuvastatin without a drug holiday while the patient has active symptoms and CK elevation at 8× ULN is not appropriate. A drug holiday is the indicated next step to allow CK normalization and symptom resolution before any rechallenge strategy is implemented.

ANSWER: E

Rationale:

The correct answer is E. Statins are contraindicated in pregnancy. Current FDA labeling states "avoid use in pregnancy" (the prior Category X designation has been replaced by the current labeling system, but the recommendation for avoidance is unchanged). The pharmacological rationale is mechanistically grounded: the mevalonate pathway — which statins inhibit — is the biosynthetic source not only of cholesterol but of isoprenoid intermediates (farnesyl pyrophosphate, geranylgeranyl pyrophosphate, dolichols) that are essential for fetal neuronal myelination, organogenesis, and steroid hormone biosynthesis (cortisol, sex steroids, aldosterone). Blocking this pathway during fetal development carries genuine teratogenic risk. The correct management is immediate discontinuation upon confirmed pregnancy. In women with FH, the statin holiday is standard of care from confirmed conception through delivery and completion of breastfeeding. For the most severe FH cases, bile acid sequestrants (which are not systemically absorbed and are not teratogenic) or ezetimibe (with careful risk-benefit assessment) may be considered for partial lipid management during pregnancy.

• Option A: Option A is incorrect because rosuvastatin — like all statins — is contraindicated in pregnancy regardless of the clinical indication. The ASCVD benefit of statins does not override the fetal safety contraindication during pregnancy. Observational data on statin exposure in pregnancy have been mixed and do not establish safety; the biological rationale for avoidance is independent of observational signal.
• Option B: Option B is incorrect because there is no evidence-based regimen of "first trimester only" dose reduction that renders statin therapy acceptable in pregnancy. Organogenesis is not the only concern — fetal myelination and steroidogenesis continue throughout all three trimesters. Dose reduction does not resolve the contraindication.
• Option C: Option C is incorrect because pravastatin does not have a pregnancy category B designation that makes it safe throughout pregnancy. Under the prior FDA category system, pravastatin was Category X (contraindicated in pregnancy) — the same as other statins. No statin is approved for use in any trimester of pregnancy.
• Option D: Option D is incorrect because continuing statin therapy until 12 weeks is not consistent with the recommendation for immediate discontinuation upon confirmed pregnancy. Additionally, characterizing all non-statin lipid-lowering therapy as inappropriate during the remainder of pregnancy is incorrect — bile acid sequestrants and ezetimibe have roles in severe FH management during pregnancy with appropriate counseling.

ANSWER: B

Rationale:

The correct answer is B. Simvastatin has a short plasma half-life (approximately 1–3 hours for simvastatin acid). Because peak plasma concentrations are transient, the timing of the dose relative to the peak period of hepatic cholesterol synthesis determines the magnitude of HMG-CoA reductase inhibition achieved. Hepatic cholesterol synthesis follows a circadian rhythm, peaking between midnight and 2 a.m. Evening dosing of short-half-life statins — simvastatin, lovastatin, pravastatin, and fluvastatin — aligns the peak plasma concentration with the period of maximal synthetic activity, producing greater LDL-C lowering than morning dosing. The patient's current practice of taking simvastatin each morning with breakfast results in peak plasma concentrations during hours when hepatic cholesterol synthesis is relatively low, representing a pharmacokinetic mismatch that reduces efficacy. She should be counseled to switch to evening dosing. This recommendation does not apply to long-half-life statins (atorvastatin, rosuvastatin, pitavastatin — half-lives >14 hours), where continuous HMG-CoA reductase inhibition throughout the dosing interval makes timing less critical; morning dosing may be preferred for those agents to improve adherence in patients with evening polypharmacy.

• Option A: Option A is incorrect because HMG-CoA reductase inhibition by statins is competitive and reversible — not irreversible. Statin binding is concentration-dependent and dissipates as plasma concentrations fall. This is precisely why timing matters for short-half-life agents: when plasma concentrations decline, enzyme activity resumes. If the period of lowest plasma concentration coincides with the period of highest cholesterol synthesis (midnight to 2 a.m. for a morning-dosed simvastatin patient), efficacy is compromised.
• Option C: Option C is incorrect because the rationale for statin dosing timing is not based on CYP3A4 circadian activity. The recommendation for evening dosing of simvastatin is driven by the nocturnal peak in hepatic cholesterol synthesis — not by enzyme availability for drug metabolism.
• Option D: Option D is incorrect because simvastatin does not have a long half-life. It is among the shortest-acting statins (half-life ~1–3 hours). Atorvastatin has a long half-life (~14 hours) and rosuvastatin longer still (~19 hours); the timing-independent claim applies to those agents — not to simvastatin.
• Option E: Option E is incorrect because CYP3A4 activity does not follow a circadian rhythm in a clinically meaningful way that would justify timing statin administration to avoid interactions. Drug-drug interactions involving CYP3A4 are determined by the presence of inhibitors or inducers — not by the time of day.

ANSWER: A

Rationale:

The correct answer is A. The most specific distinguishing feature of statin-associated autoimmune myopathy (SAAM)/immune-mediated necrotizing myopathy (IMNM) from ordinary statin-associated muscle symptoms (SAMS) is the persistence and progression of muscle weakness after statin discontinuation. In ordinary SAMS, symptoms are driven by ongoing pharmacological drug exposure — direct statin effects on mitochondrial function, isoprenoid depletion, and sarcolemmal membrane integrity. When the drug is removed, these pharmacological insults cease and symptoms resolve, typically within 4–6 weeks. In IMNM, the pathophysiology is fundamentally different: statin exposure triggers the generation of anti-HMGCR autoantibodies in genetically susceptible individuals. Once the autoimmune response is established, it becomes self-sustaining — T-cell and complement-mediated muscle fiber necrosis continues independently of further statin exposure. This is why symptoms worsen after drug withdrawal rather than improving, and it is why immunosuppressive therapy (not drug cessation alone) is required for management.

• Option B: Option B is incorrect because CK elevation above 10× ULN is not pathognomonic for IMNM. Ordinary pharmacological rhabdomyolysis from statins (or other causes) can produce CK elevations well above this threshold. CK level alone does not distinguish IMNM from severe pharmacological myopathy; the clinical trajectory after discontinuation, anti-HMGCR serology, and muscle biopsy are required for definitive differentiation.
• Option C: Option C is incorrect because proximal muscle weakness, while characteristic of IMNM, is not pathognomonic in isolation. Proximal weakness can also occur in severe pharmacological myopathy, polymyositis, dermatomyositis, and hypothyroid myopathy. The proximal distribution is a feature that supports IMNM but does not independently distinguish it from all other causes.
• Option D: Option D is incorrect because while IMNM often presents after prolonged statin exposure, there is no defined minimum duration that makes late-onset symptoms diagnostic of IMNM by timeline alone. Ordinary SAMS can also appear months or years after statin initiation, particularly when a dose increase or interacting drug is added. Duration of prior therapy is a contextual clue — not a pathognomonic distinguishing criterion.
• Option E: Option E is incorrect because myoglobinuria does not invariably accompany CK elevations of 22,000 U/L in pharmacological rhabdomyolysis. Myoglobin is cleared rapidly by the kidneys and urine myoglobinuria may be absent even at high CK levels depending on timing of measurement, hydration status, and renal function. Absence of myoglobinuria at this CK level does not confirm immune-mediated over pharmacological injury.

ANSWER: C

Rationale:

The correct answer is C. The benefit-risk relationship between statin-associated new-onset diabetes mellitus (NODM) and cardiovascular event prevention has been quantified in meta-analyses of randomized statin trials. For every 1 case of NODM attributable to statin therapy in a high-risk population, statin therapy prevents approximately 5 major cardiovascular events (myocardial infarction, stroke, cardiovascular death, or revascularization). This ratio represents a highly favorable benefit profile: even accounting for the diabetogenic risk, statin therapy substantially reduces net morbidity in the populations where it is indicated. The correct clinical implication is that statin therapy should not be withheld from patients at risk for diabetes, and that the development of NODM on statin therapy should be managed with standard diabetes care — lifestyle modification, fasting glucose monitoring, and pharmacological diabetes management if indicated — without statin discontinuation. Clinicians should counsel patients about the modest absolute diabetogenic risk and intensify lifestyle modification accordingly, but this counseling is additional to, not a substitute for, ongoing statin therapy.

• Option A: Option A is incorrect because the benefit-to-risk ratio is not neutral — approximately 5 cardiovascular events are prevented for each 1 case of NODM, strongly favoring statin use. Withholding statins from patients with pre-diabetes or metabolic syndrome on the basis of NODM risk alone is inconsistent with guideline recommendations and would deprive a high-risk group of meaningful cardiovascular protection.
• Option B: Option B is incorrect because the prevention ratio is approximately 5:1 — not 2:1. Furthermore, the 2:1 parity claim for patients with pre-existing metabolic risk reverses the actual clinical situation: patients with metabolic risk factors have the highest absolute cardiovascular risk and therefore derive the greatest absolute benefit from statin therapy, even accounting for their higher absolute NODM risk.
• Option D: Option D is incorrect because the ratio is approximately 5:1 — not 20:1. More importantly, even with a favorable ratio, statin-associated NODM is a clinically meaningful adverse effect that must be disclosed during informed consent. Patients have a right to know about diabetogenic risk; the favorable benefit-risk ratio informs clinical decision-making but does not eliminate the obligation for patient counseling.
• Option E: Option E is incorrect because the 5:1 ratio does not reverse in primary prevention to favor NODM risk over cardiovascular benefit. Patients with pre-diabetes in primary prevention settings — particularly those with multiple ASCVD risk factors — continue to derive meaningful net cardiovascular benefit from statin therapy. The 5:1 figure applies to high-risk populations; in lower-risk primary prevention populations, the absolute cardiovascular benefit is smaller, but so is the absolute NODM risk, and the ratio does not invert.

ANSWER: D

Rationale:

The correct answer is D. Rosuvastatin has a plasma half-life of approximately 19 hours — among the longest of any statin in clinical use. This pharmacokinetic property is clinically exploited in patients with statin-associated muscle symptoms (SAMS) who have failed daily dosing strategies: by administering rosuvastatin every other day or twice weekly, the average steady-state plasma concentration is reduced relative to daily dosing, decreasing the time-averaged skeletal muscle drug exposure that contributes to symptom burden. Despite reduced dosing frequency, the long half-life maintains measurable plasma concentrations between doses, and clinical studies of alternate-day and twice-weekly rosuvastatin dosing have demonstrated LDL-C reductions of approximately 20–35% — a therapeutically meaningful reduction that, when combined with ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, can approach the LDL-C targets required for secondary prevention. This strategy is explicitly recommended in stepwise SAMS management guidelines as Step 4 of the rechallenge algorithm. It is not applicable to short-half-life statins (simvastatin, lovastatin, pravastatin, fluvastatin), where the pharmacokinetic rationale does not hold.

• Option A: Option A is incorrect because rosuvastatin's hepatoselectivity, while real, does not eliminate skeletal muscle drug delivery at any dose — including the maximum approved dose. Hepatoselectivity reflects preferential hepatic uptake relative to systemic tissues, not absolute exclusion of muscle exposure. High-dose rosuvastatin 40 mg daily is more likely to produce muscle symptoms than low-dose alternate-day dosing in a genuinely SAMS-intolerant patient.
• Option B: Option B is incorrect because rosuvastatin's hydrophilic profile reduces — but does not eliminate — skeletal muscle penetration. Rosuvastatin does reach skeletal muscle at measurable concentrations, which is why SAMS can occur with rosuvastatin (albeit at lower reported rates than lipophilic statins). Claiming zero skeletal muscle penetration overstates the pharmacokinetic difference and would lead to inappropriate reassurance in a patient with known muscle symptom susceptibility.
• Option C: Option C is incorrect because once-weekly rosuvastatin does not produce LDL-C reductions equivalent to rosuvastatin 40 mg daily. The half-life of 19 hours does not support once-weekly dosing as an equivalent-efficacy strategy; drug concentrations fall substantially below therapeutically meaningful levels over a 7-day interval. The validated alternate-day and twice-weekly strategies are not equivalent to daily dosing but provide clinically useful partial LDL-C reduction — a deliberate trade-off between tolerability and efficacy.
• Option E: Option E is incorrect because randomized trials of coenzyme Q10 (CoQ10) supplementation have not demonstrated consistent benefit for statin-associated muscle symptoms. Plasma CoQ10 is consistently reduced by statins, but circulating CoQ10 levels do not reliably reflect intramuscular CoQ10 status, and CoQ10 supplementation does not reliably abolish SAMS in controlled trial conditions. Guideline recommendations do not endorse CoQ10 supplementation as a strategy that enables full statin rechallenge.